The estimated Net Worth of Kurt Von Emster is at least $73.9 millió dollars as of 29 September 2023. Mr. Emster owns over 15,921 units of Cymabay Therapeutics Inc stock worth over $3,440,314 and over the last 8 years he sold CBAY stock worth over $70,250,360. In addition, he makes $208,493 as Independent Director at Cymabay Therapeutics Inc.
Kurt has made over 47 trades of the Cymabay Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 15,921 units of CBAY stock worth $79,605 on 29 September 2023.
The largest trade he's ever made was selling 650,000 units of Cymabay Therapeutics Inc stock on 11 May 2018 worth over $35,353,500. On average, Kurt trades about 58,139 units every 42 days since 2016. As of 29 September 2023 he still owns at least 105,921 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr. Emster stock trades at the bottom of the page.
Kurt von Emster, CFA is an Independent Director. Mr. von Emster was elected to the Board because of his in-depth knowledge of the pharmaceutical industry where he has been an institutional biotechnology and health care analyst and portfolio manager for 26 years. Mr. von Emster has been a Partner at Abingworth LLP, a venture capital firm, since January 2015 and as Managing Partner since July 2015. Prior to joining Abingworth, Mr. von Emster was a co-founder and Partner of venBio LLC, a venture capital firm, from May 2009 until January 2015. In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. Mr. von Emster’s investment career started in 1989 at Franklin Templeton Investments where he founded and managed several health and biotechnology funds in the 1990s. Mr. von Emster currently serves on the board of directors of SutroVax, Inc., Jasper Therapeutics, Inc. and SFJ Pharmaceuticals Inc. He is a former member of the board of CRISPR Therapeutics, Inc., Attenua, Inc., Aurinia Pharmaceuticals, Inc., Kesios Therapeutics, Ltd., Cytos Biotechnology, Ltd. (merged with Kuros Biosurgery Holding AG), Facet Biotech Corporation (sold to Abbott Laboratories in 2010) and Somaxon Pharmaceuticals, Inc. (sold to Pernix Therapeutics Holdings, Inc. in 2013), and a former board observer of Acceleron Pharma Inc. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA). Because of his more than 25 years of experience in the biopharmaceutical industry as a portfolio manager and investor, as well as his extensive corporate governance and board oversight experience, we believe he is able to make valuable contributions to the Board.
As the Independent Director of Cymabay Therapeutics Inc, the total compensation of Kurt Emster at Cymabay Therapeutics Inc is $208,493. There are 8 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.
Kurt Emster is 52, he's been the Independent Director of Cymabay Therapeutics Inc since 2009. There are 10 older and 6 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
Kurt's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster és Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: